Institutional investors purchased a net $10.0 million shares of IMGN during the quarter ended June 2017 and now own 88.49% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
APO ASSET MANAGEMENT GMBH Bought 36.7 Thousand shares of ImmunoGen Inc
MEDICAL STRATEGY GMBH Bought 29.4 Thousand shares of ImmunoGen Inc
CONTRAVISORY INVESTMENT MANAGEME... Bought 73.00 shares of ImmunoGen Inc